Literature summary for 1.14.14.14 extracted from

Di Matteo, M.; Ammazzalorso, A.; Andreoli, F.; Caffa, I.; De Filippis, B.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Nencioni, A.; Parenti, M.D.; Soncini, D.; Del Rio, A.; Amoroso, R.
Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors (2016), Bioorg. Med. Chem. Lett., 26, 3192-3194 .

Search for more literature for 1.14.14.14

Inhibitors

Inhibitors	Comment	Organism	Structure
1-(3-bromo-4-methoxybenzene-1-sulfonyl)-3-[(1H-imidazol-1-yl)methyl]piperidine	-	Homo sapiens
1-[3-(2-chloro-6-nitrophenyl)benzene-1-sulfonyl]-3-[(1H-imidazol-1-yl)methyl]piperidine	-	Homo sapiens
4-[3-[(1H-imidazol-1-yl)methyl]piperidine-1-sulfonyl]-2,1,3-benzothiadiazole	-	Homo sapiens
SYN 20028567	nonsteroidal lead compound for aromatase inhibition	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
7-methoxy-4-trifluoromethyl coumarin + H2O + oxidized flavoprotein	-	Homo sapiens	? + O2 + reduced flavoprotein	-	?

IC50 Value

IC50 Value	IC50 Value Maximum	Comment	Organism	Inhibitor	Structure
0.000006	-	pH not specified in the publication, temperature not specified in the publication	Homo sapiens	1-(3-bromo-4-methoxybenzene-1-sulfonyl)-3-[(1H-imidazol-1-yl)methyl]piperidine
0.000007	-	pH not specified in the publication, temperature not specified in the publication	Homo sapiens	4-[3-[(1H-imidazol-1-yl)methyl]piperidine-1-sulfonyl]-2,1,3-benzothiadiazole
0.000009	-	pH not specified in the publication, temperature not specified in the publication	Homo sapiens	1-[3-(2-chloro-6-nitrophenyl)benzene-1-sulfonyl]-3-[(1H-imidazol-1-yl)methyl]piperidine
0.000009	-	pH not specified in the publication, temperature not specified in the publication	Homo sapiens	SYN 20028567

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)